Sheffield Pharmaceuticals Inc Sample Contracts

AutoNDA by SimpleDocs
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • September 30th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 26, 2024, between Theriva Biologics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

R E C I T A L :
Note Purchase Agreement • November 14th, 2001 • Sheffield Pharmaceuticals Inc • Pharmaceutical preparations • New York
BETWEEN
License Agreement • December 21st, 2001 • Sheffield Pharmaceuticals Inc • Pharmaceutical preparations • New York
UNDERWRITING AGREEMENT between SYNTHETIC BIOLOGICS, INC. and as Representative of the Several Underwriters
Underwriting Agreement • October 15th, 2018 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York

The undersigned, Synthetic Biologics, Inc., a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Synthetic Biologics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

Recitals
Purchase Agreement • January 26th, 2001 • Sheffield Pharmaceuticals Inc • Pharmaceutical preparations • New York
LEASE
Lease Agreement • November 13th, 1997 • Sheffield Pharmaceuticals Inc • Pharmaceutical preparations • Missouri
SYNTHETIC BIOLOGICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of ________, 20__ Debt Securities
Indenture • May 3rd, 2021 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York

Indenture, dated as of , 20 , among Synthetic Biologics, Inc., a Nevada corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):

ARTICLE I DEFINITIONS
Loan and Security Agreement • November 14th, 2001 • Sheffield Pharmaceuticals Inc • Pharmaceutical preparations
WITNESSETH:
Employment Agreement • March 29th, 2002 • Sheffield Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
LETTER AMENDMENT
Employment Agreement • March 28th, 1997 • Sheffield Medical Technologies Inc • Pharmaceutical preparations
SYNTHETIC BIOLOGICS, INC. Up to $ 15,000,000 of Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement
Sales Agreement • July 3rd, 2013 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York

Synthetic Biologics, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:

Exhibit 10.1 BUSINESS LOAN AGREEMENT
Business Loan Agreement • October 3rd, 2007 • Pipex Pharmaceuticals, Inc. • Pharmaceutical preparations • Michigan

THIS BUSINESS LOAN AGREEMENT dated September 27, 2007, is made and executed between PIPEX PHARMACEUTICALS, INC. ("Borrower") and Bank of Ann Arbor ("Lender") on the following terms and conditions. Borrower has received prior commercial loans from Lender or has applied to Lender for a commercial loan or loans or other financial accommodations, including those which may be described on any exhibit or schedule attached to this Agreement ("Loan"). Borrower understands and agrees that: (A) in granting, renewing, or extending any Loan, Lender is relying upon Borrower's representations, warranties, and agreements as set forth in this Agreement; (B) the granting, renewing, or extending of any Loan by Lender at all times shall be subject to Lender's sole judgment and discretion; and (C) all such Loans shall be and remain subject to the terms and conditions of this Agreement.

PRE-FUNDED COMMON STOCK PURCHASE WARRANT Theriva Biologics, Inc.
Pre-Funded Common Stock Purchase Warrant • September 30th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations

THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Theriva Biologics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

AutoNDA by SimpleDocs
COMMON STOCK PURCHASE WARRANT Theriva Biologics, Inc.
Common Stock Purchase Warrant • September 30th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Theriva Biologics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

AGREEMENT AND PLAN OF MERGER By and Among Sheffield Medical Technologies Inc.
Merger Agreement • May 14th, 1997 • Sheffield Medical Technologies Inc • Pharmaceutical preparations • New York
Amended and Restated At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • February 10th, 2021 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York
SYNTHETIC BIOLOGICS, INC. 13,333,333 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • July 17th, 2015 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York

Synthetic Biologics, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 13,333,333 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (“Common Stock”), of the Company. In addition, at the option of the Underwriters, the Company proposes to sell, subject to the terms and conditions stated herein, to the Underwriters up to an additional 2,000,000 shares of Common Stock (collectively, the “Optional Shares”). The Firm Shares and the Optional Shares are herein referred to as the “Shares”.

Synthetic Biologics, Inc. and Corporate Stock Transfer, Inc., as Warrant Agent Warrant Agency Agreement Dated as of October 15, 2018
Warrant Agency Agreement • October 15th, 2018 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York

WARRANT AGENCY AGREEMENT, dated as of October 15, 2018 (“Agreement”), between Synthetic Biologics, Inc., a Nevada corporation (the “Company”), and Corporate Stock Transfer, Inc., with offices located at 3200 Cherry Creek South Drive, Suite 430, Denver, Colorado 80209 (the “Warrant Agent”).

PLACEMENT AGENCY AGREEMENT
Placement Agency Agreement • September 30th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York
FORM OF WARRANT ADEONA PHARMACEUTICALS, INC. Warrant To Purchase Common Stock
Warrant to Purchase Common Stock • February 2nd, 2011 • Adeona Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

Adeona Pharmaceuticals, Inc., a company organized under the laws of Nevada (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [BUYER], the registered holder hereof or its permitted assigns (the "Holder"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the "Warrant"), at any time or times on or after the date hereof (the "Initial Exercisability Date"), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ______________ (_____________)1 fully paid nonassessable shares of Common Stock, par value $0.001 per share, subject to adjustment as provided herein (the "Warrant Shares"). Except as otherwise defined herein, capitalized term

AND
Subscription, Joint Development and Operating Agreement • December 21st, 2001 • Sheffield Pharmaceuticals Inc • Pharmaceutical preparations • New York
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!